DBPR-108
drugOn this page
Also known as PrusogliptinDBPR108
Summary
Dbpr-108 (CHEMBL1082462) is a phase-3 clinical-stage small molecule targeting DPP4; indicated across 3 conditions including type 2 diabetes mellitus and liver disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 1 (DPP4)
- Indications: 3 conditions
- Clinical trials: 11
- Chemistry: 324.39 Da · C16H25FN4O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1082462 |
| Name | DBPR-108 |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 44201003 |
| Molecular formula | C16H25FN4O2 |
| Molecular weight | 324.39 |
| InChIKey | VQKSCYBKUIDZEI-STQMWFEESA-N |
SMILES: CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@H](C[C@H]2C#N)F
IUPAC name: (2S,4S)-4-fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile
Also known as: Dbpr-108, DBPR-108, Prusogliptin, DBPR108
Patent coverage: 19 distinct patent families (47 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| DPP4 | dipeptidyl peptidase 4 | Inhibition | 8.3 | 0% | P27487 |
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Dipeptidyl peptidase 4.
Bioactivity
ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| DPP4 | 8.3 | IC50 | 5 | nM | CHEMBL_ACT_3313865 |
| DPP4 | 8 | IC50 | 10 | nM | CHEMBL_ACT_3313880 |
| DPP4 | 7.82 | IC50 | 15 | nM | CHEMBL_ACT_3313847 |
Target pathways
Aggregated over 1 target gene(s): DPP4.
Top Reactome pathways
2 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 1 | DPP4 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 1 | DPP4 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| behavioral fear response | 1 |
| response to hypoxia | 1 |
| proteolysis | 1 |
| cell adhesion | 1 |
| positive regulation of cell population proliferation | 1 |
| negative regulation of extracellular matrix disassembly | 1 |
| peptide hormone processing | 1 |
| receptor-mediated endocytosis of virus by host cell | 1 |
| T cell costimulation | 1 |
| regulation of cell-cell adhesion mediated by integrin | 1 |
| locomotory exploration behavior | 1 |
| psychomotor behavior | 1 |
| T cell activation | 1 |
| endothelial cell migration | 1 |
| symbiont entry into host cell | 1 |
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 8 |
| PHASE3 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07026968 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes |
| NCT04218734 | PHASE3 | COMPLETED | A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM |
| NCT04124484 | PHASE2 | COMPLETED | DBPR108 Tablets in Type 2 Diabetes Mellitus Patients |
| NCT01650324 | PHASE1 | COMPLETED | A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects |
| NCT02163278 | PHASE1 | COMPLETED | A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects |
| NCT04859426 | PHASE1 | COMPLETED | A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment |
| NCT04859439 | PHASE1 | COMPLETED | A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment |
| NCT04859452 | PHASE1 | COMPLETED | A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects |
| NCT05045313 | PHASE1 | COMPLETED | A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects |
| NCT05146869 | PHASE1 | COMPLETED | A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients |
| NCT05150626 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
28 molecules share ≥1 primary target. Top 28 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| ALOGLIPTIN | ChEMBL + PubChem | Phase 4 (approved) | DPP4 |
| LINAGLIPTIN | ChEMBL + PubChem | Phase 4 (approved) | DPP4 |
| SAXAGLIPTIN | ChEMBL + PubChem | Phase 4 (approved) | DPP4 |
| ANAGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| EVOGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| GEMIFLOXACIN | ChEMBL | Phase 4 (approved) | DPP4 |
| GOSOGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| METFORMIN | ChEMBL | Phase 4 (approved) | DPP4 |
| OMARIGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| SITAGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| TENELIGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| TRELAGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| VIDARABINE | ChEMBL | Phase 4 (approved) | DPP4 |
| VILDAGLIPTIN | ChEMBL | Phase 4 (approved) | DPP4 |
| CAFFEIC ACID | ChEMBL | Phase 3 | DPP4 |
| DUTOGLIPTIN | ChEMBL | Phase 3 | DPP4 |
| EPIGALOCATECHIN GALLATE | ChEMBL | Phase 3 | DPP4 |
| QUERCETIN | ChEMBL | Phase 3 | DPP4 |
| RESVERATROL | ChEMBL | Phase 3 | DPP4 |
| RETAGLIPTIN | ChEMBL | Phase 3 | DPP4 |
| TALABOSTAT | ChEMBL | Phase 3 | DPP4 |
| CARMEGLIPTIN | ChEMBL | Phase 2 | DPP4 |
| COFROGLIPTIN | ChEMBL | Phase 2 | DPP4 |
| FLAVONE | ChEMBL | Phase 2 | DPP4 |
| GALLIC ACID | ChEMBL | Phase 2 | DPP4 |
| GENISTEIN | ChEMBL | Phase 2 | DPP4 |
| LUTEOLIN | ChEMBL | Phase 2 | DPP4 |
| Carfilzomib | PubChem | Approved | DPP4 |
Related Atlas pages
- Genes: DPP4
- Diseases: type 2 diabetes mellitus
- Drugs: Alogliptin, Linagliptin, Saxagliptin, Anagliptin, Evogliptin, Gemifloxacin, Gosogliptin, Metformin, Omarigliptin, Sitagliptin, Teneligliptin, Trelagliptin, Vidarabine, Vildagliptin, Caffeic Acid, Dutogliptin, Epigalocatechin Gallate, Quercetin, Resveratrol, Retagliptin, Talabostat, Carfilzomib